Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents

Wegener's granulomatosis of the pituitary gland resulting in diabetes insipidus is a rare complication of the disease. Standard treatment for Wegener's granulomatosis involves a combination of prednisolone and cylophosphamide, however biologic agents are now being used in refractory cases....

Full description

Bibliographic Details
Main Authors: Joanna Rosalind Cunnington, Ramesh Jois, Ivan Zammit, David Scott, John Isaacs
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:International Journal of Rheumatology
Online Access:http://dx.doi.org/10.1155/2009/346136
id doaj-ecf04732dc794324b6900457cd1c2288
record_format Article
spelling doaj-ecf04732dc794324b6900457cd1c22882020-11-24T23:52:11ZengHindawi LimitedInternational Journal of Rheumatology1687-92601687-92792009-01-01200910.1155/2009/346136346136Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic AgentsJoanna Rosalind Cunnington0Ramesh Jois1Ivan Zammit2David Scott3John Isaacs4Musculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UKMusculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UKMusculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UKMusculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UKMusculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UKWegener's granulomatosis of the pituitary gland resulting in diabetes insipidus is a rare complication of the disease. Standard treatment for Wegener's granulomatosis involves a combination of prednisolone and cylophosphamide, however biologic agents are now being used in refractory cases. We report three cases of patients with diabetes insipidus as a complication of Wegener's granulomatosis who were treated with biologic agents. All three cases showed clinical response to treatment with biologic agents including rituximab and alemtuzumab and two cases demonstrated improvement in pituitary gland abnormalities by MRI. Clinicians should be aware that diabetes insipidus can present as a complication of Wegener's granulomatosis and that biologic therapies may be effective in refractory cases.http://dx.doi.org/10.1155/2009/346136
collection DOAJ
language English
format Article
sources DOAJ
author Joanna Rosalind Cunnington
Ramesh Jois
Ivan Zammit
David Scott
John Isaacs
spellingShingle Joanna Rosalind Cunnington
Ramesh Jois
Ivan Zammit
David Scott
John Isaacs
Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents
International Journal of Rheumatology
author_facet Joanna Rosalind Cunnington
Ramesh Jois
Ivan Zammit
David Scott
John Isaacs
author_sort Joanna Rosalind Cunnington
title Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents
title_short Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents
title_full Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents
title_fullStr Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents
title_full_unstemmed Diabetes Insipidus as a Complication of Wegener's Granulomatosis and Its Treatment with Biologic Agents
title_sort diabetes insipidus as a complication of wegener's granulomatosis and its treatment with biologic agents
publisher Hindawi Limited
series International Journal of Rheumatology
issn 1687-9260
1687-9279
publishDate 2009-01-01
description Wegener's granulomatosis of the pituitary gland resulting in diabetes insipidus is a rare complication of the disease. Standard treatment for Wegener's granulomatosis involves a combination of prednisolone and cylophosphamide, however biologic agents are now being used in refractory cases. We report three cases of patients with diabetes insipidus as a complication of Wegener's granulomatosis who were treated with biologic agents. All three cases showed clinical response to treatment with biologic agents including rituximab and alemtuzumab and two cases demonstrated improvement in pituitary gland abnormalities by MRI. Clinicians should be aware that diabetes insipidus can present as a complication of Wegener's granulomatosis and that biologic therapies may be effective in refractory cases.
url http://dx.doi.org/10.1155/2009/346136
work_keys_str_mv AT joannarosalindcunnington diabetesinsipidusasacomplicationofwegenersgranulomatosisanditstreatmentwithbiologicagents
AT rameshjois diabetesinsipidusasacomplicationofwegenersgranulomatosisanditstreatmentwithbiologicagents
AT ivanzammit diabetesinsipidusasacomplicationofwegenersgranulomatosisanditstreatmentwithbiologicagents
AT davidscott diabetesinsipidusasacomplicationofwegenersgranulomatosisanditstreatmentwithbiologicagents
AT johnisaacs diabetesinsipidusasacomplicationofwegenersgranulomatosisanditstreatmentwithbiologicagents
_version_ 1725474310594756608